B+
Bull case
25%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
LFST
Lifestance Health GroupCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$12.70
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$8.80
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+56.3
Score
AI commentary
News tone is positive following the confirmed company earnings release, raised FY outlook, and repurchase announcement. The anchor price was $10.84 on August 7, and the latest quote was modestly higher, but no trusted source attributes the move to results, guidance, or commentary. Post-print analyst revisions are unavailable, so confidence remains tentative and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-06eventConfirmed Q2 results and raised FY 2026 outlookHigh impact
LifeStance's August 6, 2026 Form 8-K exhibit reported Q2 revenue of $435.4 million, up 26%, Adjusted EBITDA of $66.0 million, up 94%, raised full-year revenue and EBITDA ranges, and announced a $100 million repurchase program. [#SEC-8K-2026-08-06]
2026-11-06catalystPost-earnings follow-through and valuation riskMedium impact
The latest quote was $10.84, up 1.5% from the prior close, but post-print analyst revisions and market-attribution data remain unavailable. A high valuation could amplify downside if growth or margin momentum moderates.
2027-08-08catalystClinician and visit-volume operating leverageHigh impact
Clinicians increased 11% to 8,542 and visits increased 19% to 2.6 million, supporting higher revenue per visit, margin expansion, and stronger cash generation. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology